Moderna Surges After Historic Phase 3 Success for First mRNA Cancer Therapy
Moderna shares surged after positive Phase 3 results for the first successful mRNA cancer therapy, adding more than $50 billion in market value.
#Pharmaceuticals
Explore MarketSpeaker's latest reporting, research, and expert analysis tagged with "pharmaceuticals", collected in one continuously updated archive.
Related Posts
AstraZeneca and Bristol Myers Hold Merger Talks in Potential $400 Billion Deal
AstraZeneca and Bristol Myers Squibb have held discussions about a potential merger valued at more than $400 billion, a deal that would create one of the world’s largest pharmaceutical companies.
Novo Nordisk Partners With OpenAI to Accelerate AI-Driven Drug Discovery
Novo Nordisk has partnered with OpenAI to enhance its drug discovery efforts using advanced AI tools, aiming to accelerate identification of new treatments.
Eli Lilly Strikes Up to $2.75 Billion AI Drug Deal With Insilico Medicine
By
Emma Clarke
• 2 mins read
Eli Lilly will pay up to $2.75 billion to bring AI-developed drugs from Insilico Medicine to market. The deal highlights growing momentum in AI-driven drug discovery.
Novartis Acquires Excellergy for $2 Billion in Immunology Push
By
Emma Clarke
• 2 mins read
Novartis has agreed to acquire immunology biotech Excellergy for $2 billion, marking its second major deal in a week. The move strengthens its pipeline in next-generation allergy treatments.
Recursion Pharmaceuticals
By
Emma Clarke
• 3 mins read
Recursion Pharmaceuticals, Inc. is an American clinical-stage biotechnology company that uses automated experiments, biological datasets, computing, and machine learning in drug discovery. It develops its own medicine candidates and conducts research programs with pharmaceutical partners.